-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: drug risks
Atriphen dietary supplement Xymogen brand Recall
Translation Atriphen dietary supplement (Xymogen brand): Recall – Potential Allergic Reaction Due to Milk and Soy AUDIENCE: Consumer, Health Professional ISSUE: The nutraceutical company, Xymogen, (Orlando, FL) and FDA, are notifying consumers and health professionals of the recall of Atriphen, a … Continue reading
Posted in Consumer Products, FDA 2013, FDA Recall, Healthcare Professionals
Tagged Atriphen, Atriphen dietary supplement Xymogen brand Recall, dietary supplement, drug risks, FDA recall, Recall, Xymogen brand
Comments Off
The Compounding Shop FDA News Release
TranslationThe Compounding Shop: FDA News Release – Lack of Sterility Assurance of Drug Products AUDIENCE: Pharmacy, Healthcare Professionals, Patients ISSUE: The U.S. Food and Drug Administration is alerting health care providers, hospital supply managers, and pharmacists that the FDA’s preliminary … Continue reading
Posted in FDA 2013, FDA Safety Communication, Healthcare Professionals, Patients, Pharmacy
Tagged drug risks, Drug Safety Communication, FDA News Release, FDA notice, Healthcare Professionals, Patients, Pharmacy, Safety Communication, The Compounding Shop, The Compounding Shop: FDA News Release
Comments Off
Kadcyla ado-trastuzumab emtansine Drug Safety Communication
TranslationKadcyla (ado-trastuzumab emtansine): Drug Safety Communication – Potential Medication Errors Resulting from Name Confusion AUDIENCE: Risk Manager, Pharmacy, Oncology ISSUE: The FDA notified health care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla … Continue reading
Anticoagulant Citrate Phosphate Dextrose Solution USP (CPD) BLOOD-PACK Unit Fenwal Recall
TranslationAnticoagulant Citrate Phosphate Dextrose Solution, USP (CPD) BLOOD-PACK Unit By Fenwal: Recall – Labeling Issue Identified Read the MedWatch Safety Alert, including links to the Recall at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350275.htm AUDIENCE: Risk Manager, Health Professional, Pharmacy ISSUE: Fenwal has initiated a … Continue reading
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Pharmacy, Risk Manager
Tagged (CPD), Anticoagulant Citrate Phosphate Dextrose Solution, Anticoagulant Citrate Phosphate Dextrose Solution USP (CPD) BLOOD-PACK Unit Fenwal Recall, BLOOD-PACK Unit, Dietary Supplements, drug risks, FDA recall, Fenwal, Health Professional, Pharmacy, Recall, Risk Manager, Risk Managers, USP)
Comments Off
Samsca Tolvaptan Drug Safety Communication
TranslationSamsca (Tolvaptan): Drug Safety Communication – FDA Limits Duration and Usage Due To Possible Liver Injury Leading to Organ Transplant or Death AUDIENCE: Pharmacy, Health Professional, Patient ISSUE: FDA has determined that the drug Samsca (tolvaptan) should not be used … Continue reading
Posted in FDA 2013, FDA Safety Communication, Healthcare Professionals, Patients, Pharmacy
Tagged drug risks, Drug Safety Communication, FDA notice, Health Professional, Patient, Pharmacy, Risk Managers, Safety Communication, Samsca, Samsca Tolvaptan Drug Safety Communication, tolvaptan
Comments Off
Piperacillin Tazobactam Injection USP 40.5 grams Recall
TranslationPiperacillin and Tazobactam for Injection, USP 40.5 grams: Recall – Precipitation or Crystallization in IV Bag or IV Line Upon Reconstitution AUDIENCE: Risk Manager, Nursing, Health Professional ISSUE: Apotex Corp. notified healthcare professionals it is conducting, on behalf of the … Continue reading
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Nursing, Risk Manager
Tagged drug risks, FDA recall, Health Professional, Injection, Nursing, Piperacillin, Piperacillin Tazobactam Injection USP 40.5 grams Recall, Recall, Risk Manager, Tazobactam, USP 40.5 grams
Comments Off
Potiga Ezogabine Drug Safety Communication
TranslationPotiga (Ezogabine): Drug Safety Communication – Linked To Retinal Abnormalities And Blue Skin Discoloration AUDIENCE: Health Professional, Neurology, Patient ISSUE: FDA is warning the public that the anti-seizure medication Potiga (Ezogabine) can cause blue skin discoloration and eye abnormalities characterized … Continue reading
Posted in FDA 2013, FDA Safety Communication, Healthcare Professionals, Neurology, Patients
Tagged Blue Skin Discoloration, drug risks, Drug Safety Communication, Ezogabine, FDA notice, Health Professional, Neurology, Patient, Potiga, Potiga Ezogabine Drug Safety Communication, Retinal Abnormalities, Safety Communication
Comments Off
Eba Multivitamin Supplement Saratoga Therapeutics LLC Recall
TranslationEba Multivitamin Supplement By Saratoga Therapeutics LLC: Recall – Allergy Alert On Undeclared Milk Components AUDIENCE: Consumer, Patient, Health Professional ISSUE: Saratoga Therapeutics, LLC of North Wales, PA recalled 900 bottles of ebA Multivitamin Supplement because they may contain undeclared … Continue reading
Posted in Consumer Products, FDA 2013, FDA Recall, Healthcare Professionals, Patients
Tagged Consumer, Consumer Products, drug risks, Eba Multivitamin Supplement, Eba Multivitamin Supplement Saratoga Therapeutics LLC Recall, FDA recall, FDA warning, Health Professional, Patient, Recall, Saratoga Therapeutics LLC
Comments Off
Sodium Chloride Injection 0.9 percent USP Hospira Recall
TranslationSodium Chloride Injection 0.9 percent USP, 100 mL Flexible Containers by Hospira: Recall – Particulate Matter AUDIENCE: Pharmacy, Patient, Health Professional ISSUE: Hospira notified the public that last August it initiated a voluntary nationwide user-level recall of one lot of … Continue reading
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Patients, Pharmacy
Tagged 09 percent USP, 100 mL Flexible Containers, drug risks, FDA recall, Health Professional, Hospira, Hospira Recall, Patient, Pharmacy, Recall, Sodium Chloride Injection, Sodium Chloride Injection 09 percent USP 100 mL Flexible Containers
Comments Off
GE Healthcare Giraffe OmniBed Giraffe Incubator Class I Recall
TranslationGE Healthcare, Giraffe OmniBed and Giraffe Incubator: Class I Recall – Device May Randomly Delete Stored Information When Powered On AUDIENCE: Risk Manager, Biomedical Engineer ISSUE: The Giraffe Incubator and Giraffe OmniBed may randomly delete stored information and enter new … Continue reading
Posted in Biomedical Engineering, FDA 2013, FDA Recall, Risk Manager
Tagged Biomedical Engineering, Class 1 Recall, Class I Recall, drug risks, FDA recall, GE Healthcare, GE Healthcare Giraffe OmniBed Giraffe Incubator Class I Recall, Giraffe Incubator, Giraffe OmniBed, Recall, Risk Manager, Risk Managers
Comments Off